ASX BRIEFS

AMPLIA THERAPEUTICS LTD (ATX) - Narmafotinib And Pancreatic Cancer Progress

• Andrew Musgrave

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 14:53

Send us Fan Mail

Five complete responses in advanced pancreatic cancer should make anyone in biotech sit up. We’re joined by Dr Chris Burns, CEO and Managing Director of Amplia Therapeutics, to unpack what the latest mature ACCENT trial data really says about narmafotinib when it’s added to standard chemotherapy with gemcitabine and Abraxane and why “making other drugs work better” is more than a slogan when patients are running out of time.

We talk through the headline numbers, including an 11.1 month median overall survival signal and what “complete response” means in practical clinical terms. Just as important, we dig into tolerability: the combination appears to keep the side effect burden largely in line with chemotherapy alone, which is critical for any add on cancer therapy hoping to move into larger, registration enabling studies. We also explore how the US FDA fast track designation helps shape timelines and strengthens discussions with potential partners watching the pancreatic cancer pipeline closely.

Not every combo is worth forcing, and are transparent about that. We cover the recruitment halt in the AMPLICITY trial pairing narmafotinib with the more aggressive FOLFIRINOX regimen, why the limiting toxicity was linked to the chemotherapy, and how the broader landscape is shifting toward targeted and personalised medicines, including emerging RAS inhibitors. We finish with the commercial foundations, from key patents extending protection to at least 2040 in major markets to the next 12 months of milestones across pancreatic and ovarian cancer.

If you want clear, investor friendly context on pancreatic cancer drug development, clinical trial readouts, FDA pathways, and partnering strategy, hit play. Subscribe, share this with someone following oncology breakthroughs, and leave us a review with the one result you’ll be watching next.